

Sec.		Sec.	
	(j) Representation for special dietary use.		(c) Approval or denial of petition; time for issuance of order; evaluation of data; factors.
	(k) Artificial flavoring, artificial coloring, or chemical preservatives.		(d) Regulation issued on Secretary's initiative.
	(l) Pesticide chemicals on raw agricultural commodities.		(e) Publication and effective date of orders.
	(m) Color additives.		(f) Objections and public hearing; basis and contents of order; statement.
	(n) Packaging or labeling of drugs in violation of regulations.		(g) Judicial review.
	(o),		(h) Notification relating to food contact substance.
	(p) Repealed.		(i) Amendment or repeal of regulations.
	(q) Nutrition information.		(j) Exemptions for investigational use.
	(r) Nutrition levels and health-related claims.		
	(s) Dietary supplements.	349.	Bottled drinking water standards; publication in Federal Register.
343-1.	National uniform nutrition labeling.	350.	Vitamins and minerals.
343-2.	Dietary supplement labeling exemptions.		(a) Authority and limitations of Secretary; applicability.
	(a) In general.		(b) Labeling and advertising requirements for foods.
	(b) Application.		(c) Definitions.
	(c) Burden of proof.	350a.	Infant formulas.
343-3.	Disclosure.		(a) Adulteration.
343a.	Repealed.		(b) Requirements for quality factors, good manufacturing practices, and retention of records.
344.	Emergency permit control.		(c) Registration of persons distributing new infant formula.
	(a) Conditions on manufacturing, processing, etc., as health measure.		(d) Submission of information about new infant formula required.
	(b) Violation of permit; suspension and reinstatement.		(e) Additional notice requirements for manufacturer.
	(c) Inspection of permit-holding establishments.		(f) Procedures applicable to recalls by manufacturer; regulatory oversight.
345.	Regulations making exemptions.		(g) Recordkeeping requirements for manufacturer; regulatory oversight and enforcement.
346.	Tolerances for poisonous or deleterious substances in food; regulations.		(h) Exemptions; regulatory oversight.
346a.	Tolerances and exemptions for pesticide chemical residues.		(i) Nutrient requirements.
	(a) Requirement for tolerance or exemption.	350b.	New dietary ingredients.
	(b) Authority and standard for tolerance.		(a) In general.
	(c) Authority and standard for exemptions.		(b) Petition.
	(d) Petition for tolerance or exemption.		(c) "New dietary ingredient" defined.
	(e) Action on Administrator's own initiative.	SUBCHAPTER V—DRUGS AND DEVICES	
	(f) Special data requirements.	PART A—DRUGS AND DEVICES	
	(g) Effective date, objections, hearings, and administrative review.	351.	Adulterated drugs and devices.
	(h) Judicial review.		(a) Poisonous, insanitary, etc., ingredients; adequate controls in manufacture.
	(i) Confidentiality and use of data.		(b) Strength, quality, or purity differing from official compendium.
	(j) Status of previously issued regulations.		(c) Misrepresentation of strength, etc., where drug is unrecognized in compendium.
	(k) Transitional provision.		(d) Mixture with or substitution of another substance.
	(l) Harmonization with action under other laws.		(e) Devices not in conformity with performance standards.
	(m) Fees.		(f) Certain class III devices.
	(n) National uniformity of tolerances.		(g) Banned devices.
	(o) Consumer right to know.		(h) Manufacture, packing, storage, or installation of device not in conformity with applicable requirements or conditions.
	(p) Estrogenic substances screening program.		(i) Failure to comply with requirements under which device was exempted for investigational use.
	(q) Schedule for review.	352.	Misbranded drugs and devices.
	(r) Temporary tolerance or exemption.		(a) False or misleading label.
	(s) Savings clause.		(b) Package form; contents of label.
346b.	Authorization of appropriations.		(c) Prominence of information on label.
347.	Intrastate sales of colored oleomargarine.		(d) Repealed.
	(a) Law governing.		(e) Designation of drugs or devices by established names.
	(b) Labeling and packaging requirements.		(f) Directions for use and warnings on label.
	(c) Sales in public eating places.		
	(d) Exemption from labeling requirements.		
	(e) Color content of oleomargarine.		
347a.	Congressional declaration of policy regarding oleomargarine sales.		
347b.	Contravention of State laws.		
348.	Food additives.		
	(a) Unsafe food additives; exception for conformity with exemption or regulation.		
	(b) Petition for regulation prescribing conditions of safe use; contents; description of production methods and controls; samples; notice of regulation.		

Sec.		Sec.	
	(g) Representations as recognized drug; packing and labeling; inconsistent requirements for designation of drug.		(g) Service of orders.
	(h) Deteriorative drugs; packing and labeling.		(h) Appeal from order.
	(i) Drug; misleading container; imitation; offer for sale under another name.		(i) Exemptions of drugs for research; discretionary and mandatory conditions; direct reports to Secretary.
	(j) Health-endangering when used as prescribed.		(j) Abbreviated new drug applications.
	(k), (l) Repealed.		(k) Records and reports; required information; regulations and orders; access to records.
	(m) Color additives; packing and labeling.		(l) Public disclosure of safety and effectiveness data.
	(n) Prescription drug advertisements: established name; quantitative formula; side effects, contraindications, and effectiveness; prior approval; false advertising; labeling; construction of the Convention on Psychotropic Substances.		(m) "Patent" defined.
	(o) Drugs or devices from nonregistered establishments.	355a.	(n) Scientific advisory panels.
	(p) Packaging or labeling of drugs in violation of regulations.		Pediatric studies of drugs.
	(q) Restricted devices using false or misleading advertising or used in violation of regulations.		(a) Definitions.
	(r) Restricted devices not carrying requisite accompanying statements in advertisements and other descriptive printed matter.		(b) Market exclusivity for new drugs.
	(s) Devices subject to performance standards not bearing requisite labeling.		(c) Market exclusivity for already-marketed drugs.
	(t) Devices for which there has been a failure or refusal to give required notification or to furnish required material or information.		(d) Conduct of pediatric studies.
353.	Exemptions and consideration for certain drugs, devices, and biological products.		(e) Delay of effective date for certain application.
	(a) Regulations for goods to be processed, labeled, or repacked elsewhere.		(f) Notice of determinations on studies requirement.
	(b) Prescription by physician; exemption from labeling and prescription requirements; misbranded drugs; compliance with narcotic and marihuana laws.		(g) Limitations.
	(c) Sales restrictions.		(h) Relationship to regulations.
	(d) Distribution of drug samples.		(i) Labeling supplements.
	(e) Wholesale distributors; guidelines for licensing; definitions.		(j) Dissemination of pediatric information.
	(f) Veterinary prescription drugs.		(k) Clarification of interaction of market exclusivity under this section and market exclusivity awarded to an applicant for approval of a drug under section 355(j) of this title.
	(g) Regulation of combination products.		(l) Prompt approval of drugs under section 355(j) of this title when pediatric information is added to labeling.
353a.	Pharmacy compounding.		(m) Report.
	(a) In general.		(n) Sunset.
	(b) Compounded drug.	355b.	Adverse-event reporting.
	(c) Advertising and promotion.		(a) Toll-free number in labeling.
	(d) Regulations.		(b) Drugs with pediatric market exclusivity.
	(e) Application.	356.	Fast track products.
	(f) "Compounding" defined.		(a) Designation of drug as fast track product.
354.	Veterinary feed directive drugs.		(b) Approval of application for fast track product.
	(a) Lawful veterinary feed directive requirement.		(c) Review of incomplete applications for approval of fast track product.
	(b) Labeling and advertising.		(d) Awareness efforts.
	(c) Nonprescription status.	356a.	Manufacturing changes.
355.	New drugs.		(a) In general.
	(a) Necessity of effective approval of application.		(b) Validation of effects of changes.
	(b) Filing application; contents.		(c) Major manufacturing changes.
	(c) Period for approval of application; period for, notice, and expedition of hearing; period for issuance of order.	356b.	Reports of postmarketing studies.
	(d) Grounds for refusing application; approval of application; "substantial evidence" defined.		(a) Submission.
	(e) Withdrawal of approval; grounds; immediate suspension upon finding imminent hazard to public health.		(b) Consideration of information as public information.
	(f) Revocation of order refusing, withdrawing or suspending approval of application.	356c.	Discontinuance of life saving product.
			(a) In general.
			(b) Reduction in notification period.
			(c) Distribution.
		357.	Repealed.
		358.	Authority to designate official names.
			(a) Necessity or desirability; use in official compendiums; infringement of trademarks.
			(b) Review of names in official compendiums.
			(c) Determinations of complexity, usefulness, multiplicity, or lack of name; designation by Secretary.
			(d) Revised official names; compilation, publication, and public distribution of listings.
			(e) Request by compiler of official compendium for designation of name.

Sec. 359. 360.	Nonapplicability of subchapter to cosmetics. Registration of producers of drugs or devices. (a) Definitions. (b) Annual registration. (c) New producers. (d) Additional establishments. (e) Registration number; uniform system for identification of devices intended for human use. (f) Availability of registrations for inspection. (g) Exclusions from application of section. (h) Inspection of premises. (i) Registration of foreign establishments. (j) Filing of lists of drugs and devices manufactured, prepared, propagated and compounded by registrants; statements; accompanying disclosures. (k) Report preceding introduction of devices into interstate commerce. (l) Exemption from reporting requirements. (m) List of exempt class II devices; determination by Secretary; publication in Federal Register. (n) Review of report; time for determination by Secretary.	Sec.  360c.	(o) "Patent" defined. (p) Safety and effectiveness data. Classification of devices intended for human use. (a) Classes of devices. (b) Classification panels. (c) Classification panel organization and operation. (d) Panel recommendation; publication; priorities. (e) Classification changes. (f) Initial classification and reclassification of certain devices. (g) Information. (h) Definitions. (i) Substantial equivalence.
360a.	Repealed.	360d.	Performance standards. (a) Reasonable assurance of safe and effective performance; periodic evaluation. (b) Establishment of a standard. (c) Recognition of standard.
360b.	New animal drugs. (a) Unsafe new animal drugs and animal feed containing such drugs; conditions of safety; exemption of drugs for research; import tolerances. (b) Filing application for uses of new animal drug; contents; patent information; abbreviated application; pre-submission conference. (c) Period for submission and approval of application; period for notice and expedition of hearing; period for issuance of order; abbreviated applications; withdrawal periods; effective date of approval; relationship to other applications; withdrawal or suspension of approval; bioequivalence; filing of additional patent information. (d) Grounds for refusing application; approval of application; factors; "substantial evidence" defined; combination drugs. (e) Withdrawal of approval; grounds; immediate suspension upon finding imminent hazard to health of man or animals. (f) Revocation of order refusing, withdrawing or suspending approval of application. (g) Service of orders. (h) Appeal from order. (i) Publication in Federal Register; effective date and revocation or suspension of regulation. (j) Exemption of drugs for research; discretionary and mandatory conditions. (k) Food containing new animal drug considered unadulterated while approval of application for such drug is effective. (l) Records and reports; required information; regulations and orders; examination of data; access to records. (m) Feed mill licenses. (n) Abbreviated applications for new animal drugs; contents, filing, etc.; lists of approved drugs.	360e.	Premarket approval. (a) General requirement. (b) Regulation to require premarket approval. (c) Application for premarket approval. (d) Action on application for premarket approval. (e) Withdrawal and temporary suspension of approval of application. (f) Product development protocol. (g) Review. (h) Service of orders. (i) Revision.
		360f.	Banned devices. (a) General rule. (b) Special effective date.
		360g.	Judicial review. (a) Petition; record. (b) Additional data, views, and arguments. (c) Standard for review. (d) Finality of judgments. (e) Remedies. (f) Statement of reasons.
		360h.	Notification and other remedies. (a) Notification. (b) Repair, replacement, or refund. (c) Reimbursement. (d) Effect on other liability. (e) Recall authority.
		360i.	Records and reports on devices. (a) General rule. (b) User reports. (c) Persons exempt. (d) Repealed. (e) Device tracking. (f) Reports of removals and corrections.
		360j.	General provisions respecting control of devices intended for human use. (a) General rule. (b) Custom devices. (c) Trade secrets. (d) Notices and findings. (e) Restricted devices. (f) Good manufacturing practice requirements. (g) Exemption for devices for investigational use. (h) Release of information respecting safety and effectiveness. (i) Proceedings of advisory panels and committees. (j) Traceability. (k) Research and development. (l) Transitional provisions for devices considered as new drugs. (m) Humanitarian device exemption.

- Sec.  
360k. State and local requirements respecting devices.  
    (a) General rule.  
    (b) Exempt requirements.
- 360l. Postmarket surveillance.  
    (a) In general.  
    (b) Surveillance approval.
- 360m. Accredited persons.  
    (a) In general.  
    (b) Accreditation.  
    (c) Duration.

## PART B—DRUGS FOR RARE DISEASES OR CONDITIONS

- 360aa. Recommendations for investigations of drugs for rare diseases or conditions.  
    (a) Request by sponsor; response by Secretary.  
    (b) Regulations.
- 360bb. Designation of drugs for rare diseases or conditions.  
    (a) Request by sponsor; preconditions; “rare disease or condition” defined.  
    (b) Notification of discontinuance of drug or application as condition.  
    (c) Notice to public.  
    (d) Regulations.
- 360cc. Protection for drugs for rare diseases or conditions.  
    (a) Exclusive approval, certification, or license.  
    (b) Exceptions.
- 360dd. Open protocols for investigations of drugs for rare diseases or conditions.
- 360ee. Grants and contracts for development of drugs for rare diseases and conditions.  
    (a) Authority of Secretary.  
    (b) Definitions.  
    (c) Authorization of appropriations.

## PART C—ELECTRONIC PRODUCT RADIATION CONTROL

- 360hh. Definitions.
- 360ii. Program of control.  
    (a) Establishment.  
    (b) Powers of Secretary.  
    (c) Record keeping.
- 360jj. Studies by the Secretary.  
    (a) Report to Congress.  
    (b) Participation of other Federal agencies.  
    (c) Organization of studies and participation.
- 360kk. Performance standards for electronic products.  
    (a) Promulgation of regulations.  
    (b) Administrative procedure.  
    (c) Publication in Federal Register.  
    (d) Judicial review.  
    (e) Availability of record.  
    (f) Technical Electronic Product Radiation Safety Standards Committee.  
    (g) Review and evaluation.  
    (h) Product certification.
- 360ll. Notification of defects in and repair or replacement of electronic products.  
    (a) Notification; exemption.  
    (b) Method of notification.  
    (c) Requisite elements of notification.  
    (d) Copies to Secretary of communications by manufacturers to dealers or distributors regarding defects.  
    (e) Notice from Secretary to manufacturer of defects or failure to comply with standards.  
    (f) Correction of defects.  
    (g) Effective date.
- 360mm. Imports.  
    (a) Refusal of admission to noncomplying electronic products.

- Sec.  
    (b) Bond.  
    (c) Liability of owner or consignee for expenses connected with refusal of admission.  
    (d) Designation of agent for purposes of service.
- 360nn. Inspection, records, and reports.  
    (a) Inspection of premises.  
    (b) Record keeping.  
    (c) Disclosure of technical data.  
    (d) Public nature of reports.  
    (e) Trade secrets.  
    (f) Information required to identify and locate first purchasers of electronic products.
- 360oo. Prohibited acts.
- 360pp. Enforcement.  
    (a) Jurisdiction of courts.  
    (b) Penalties.  
    (c) Venue; process.  
    (d) Warnings.  
    (e) Compliance with regulations.  
    (f) Additional remedies.
- 360qq. Repealed.
- 360rr. Federal-State cooperation.
- 360ss. State standards.

## PART D—DISSEMINATION OF TREATMENT INFORMATION

- 360aaa. Requirements for dissemination of treatment information on drugs or devices.  
    (a) In general.  
    (b) Specific requirements.  
    (c) Additional information.
- 360aaa-1. Information authorized to be disseminated.  
    (a) Authorized information.  
    (b) Reference publication.
- 360aaa-2. Establishment of list of articles and publications disseminated and list of providers that received articles and reference publications.  
    (a) In general.  
    (b) Records.
- 360aaa-3. Requirement regarding submission of supplemental application for new use; exemption from requirement.  
    (a) In general.  
    (b) Certification on supplemental application; condition in case of completed studies.  
    (c) Certification on supplemental application; condition in case of planned studies.  
    (d) Exemption from requirement of supplemental application.  
    (e) Requirements regarding applications.
- 360aaa-4. Corrective actions; cessation of dissemination.  
    (a) Postdissemination data regarding safety and effectiveness.  
    (b) Cessation of dissemination.  
    (c) Corrective actions by manufacturers.
- 360aaa-5. Definitions.
- 360aaa-6. Rules of construction.  
    (a) Unsolicited request.  
    (b) Dissemination of information on drugs or devices not evidence of intended use.  
    (c) Patent protection.  
    (d) Authorization for dissemination of articles and fees for reprints of articles.

## PART E—GENERAL PROVISIONS RELATING TO DRUGS AND DEVICES

- 360bbb. Expanded access to unapproved therapies and diagnostics.  
    (a) Emergency situations.  
    (b) Individual patient access to investigational products intended for serious diseases.

Sec.		Sec.						
	(c) Treatment investigational new drug applications and treatment investigational device exemptions.	379d.	Automation of Food and Drug Administration.					
	(d) Termination.		(a) In general.					
	(e) Definitions.		(b) Authorization of appropriations.					
360bbb-1.	Dispute resolution.		PART B—COLORS					
360bbb-2.	Classification of products.	379e.	Listing and certification of color additives for foods, drugs, devices, and cosmetics.					
	(a) Request.		(a) Unsafe color additives.					
	(b) Statement.		(b) Listing of colors; regulations; issuance, amendment or repeal; referral to advisory committee; report and recommendations; appointment and compensation of advisory committee.					
	(c) Inaction of Secretary.		(c) Certification of colors.					
	SUBCHAPTER VI—COSMETICS		(d) Procedure for issuance, amendment, or repeal of regulations.					
361.	Adulterated cosmetics.		(e) Fees.					
362.	Misbranded cosmetics.		(f) Exemptions.					
363.	Regulations making exemptions.		PART C—FEES					
364.	Repealed.		SUBPART 1—FREEDOM OF INFORMATION FEES					
	SUBCHAPTER VII—GENERAL AUTHORITY		379f.	Recovery and retention of fees for freedom of information requests.				
	PART A—GENERAL ADMINISTRATIVE PROVISIONS			(a) In general.				
371.	Regulations and hearings.			(b) Use of fees.				
	(a) Authority to promulgate regulations.			(c) Waiver of fees.				
	(b) Regulations for imports and exports.			SUBPART 2—FEES RELATING TO DRUGS				
	(c) Conduct of hearings.			379g.	Definitions.			
	(d) Effectiveness of definitions and standards of identity.			379h.	Authority to assess and use drug fees.			
	(e) Procedure for establishment.				(a) Types of fees.			
	(f) Review of order.				(b) Fee amounts.			
	(g) Copies of records of hearings.				(c) Adjustments.			
	(h) Guidance documents.				(d) Fee waiver or reduction.			
372.	Examinations and investigations.				(e) Effect of failure to pay fees.			
	(a) Authority to conduct.				(f) Assessment of fees.			
	(b) Availability to owner of part of analysis samples.				(g) Crediting and availability of fees.			
	(c) Records of other departments and agencies.				(h) Collection of unpaid fees.			
	(d) Information on patents for drugs.				(i) Written requests for waivers, reductions, and refunds.			
	(e) Powers of enforcement personnel.				(j) Construction.			
372a.	Transferred.				PART D—INFORMATION AND EDUCATION			
373.	Records of interstate shipment.				379k.	Information system.		
374.	Inspection.				379l.	Education.		
	(a) Right of agents to enter; scope of inspection; notice; promptness; exclusions.					(a) In general.		
	(b) Written report to owner; copy to Secretary.					(b) Intramural fellowships and other training programs.		
	(c) Receipt for samples taken.					PART E—ENVIRONMENTAL IMPACT REVIEW		
	(d) Analysis of samples furnished owner.					379o.	Environmental impact.	
	(e) Accessibility of records.					PART F—NATIONAL UNIFORMITY FOR NONPRESCRIPTION DRUGS AND PREEMPTION FOR LABELING OR PACKAGING OF COSMETICS		
	(f) Recordkeeping.					379r.	National uniformity for nonprescription drugs.	
375.	Publicity.						(a) In general.	
	(a) Reports.						(b) Exemption.	
	(b) Information regarding certain goods.						(c) Scope.	
376.	Examination of sea food on request of packer; marking food with results; fees; penalties.						(d) Exceptions.	
377.	Revision of United States Pharmacopoeia; development of analysis and mechanical and physical tests.						(e) No effort on product liability law.	
							(f) State enforcement authority.	
378.	Advertising of foods.					379s.	Preemption for labeling or packaging of cosmetics.	
	(a) Determination of misbranding; notification of Federal Trade Commission by Secretary; contents.						(a) In general.	
	(b) Action by Federal Trade Commission precluding action by Secretary; exception.						(b) Exemption.	
	(c) Secretary's determination of imminent hazard to health as suspending applicability of provisions.						(c) Scope.	
	(d) Coordination of action by Secretary with Federal Trade Commission.						(d) No effect on product liability law.	
379.	Confidential information.						(e) State initiative.	
379a.	Presumption of existence of jurisdiction.						PART G—SAFETY REPORTS	
379b.	Consolidated administrative and laboratory facility.						379v.	Safety report disclaimers.
	(a) Authority.							SUBCHAPTER VIII—IMPORTS AND EXPORTS
	(b) Awarding of contract.						381.	Imports and exports.
	(c) Donations.							
	(d) Authorization of appropriations.							
379c.	Transferred.							

Sec.

- (a) Imports; list of registered foreign establishments; samples from un-registered foreign establishments; examination and refusal of admission.
  - (b) Disposition of refused articles.
  - (c) Charges concerning refused articles.
  - (d) Reimportation.
  - (e) Exports.
  - (f) Labeling of exported drugs.
  - (g) Warning notice of importation in violation of chapter.
  - 382. Exports of certain unapproved products.
    - (a) Drugs or devices intended for human or animal use which require approval or licensing.
    - (b) List of eligible countries for export; criteria for addition to list; direct export; petition for exemption.
    - (c) Investigational use exemption.
    - (d) Anticipation of market authorization.
    - (e) Diagnosis, prevention, or treatment of tropical disease.
    - (f) Prohibition of export of drug or device.
    - (g) Notification of Secretary.
    - (h) References to Secretary and term "drug".
    - (i) Exportation.
  - 383. Office of International Relations.
    - (a) Establishment.
    - (b) Agreements with foreign countries.
    - (c) Harmonizing regulatory requirements.
  - 384. Importation of covered products.
    - (a) Regulations.
    - (b) Limitation.
    - (c) Records.
    - (d) Importation.
    - (e) Testing.
    - (f) Country limitation.
    - (g) Suspension of importations.
    - (h) Prohibited agreements.
    - (i) Studies; reports.
    - (j) Construction.
    - (k) Definitions.
    - (l) Conditions.
    - (m) Sunset.
- SUBCHAPTER IX—MISCELLANEOUS
- 391. Separability clause.
  - 392. Exemption of meats and meat food products.
    - (a) Law determinative of exemption.
    - (b) Laws unaffected.
  - 393. Food and Drug Administration.
    - (a) In general.
    - (b) Mission.
    - (c) Interagency collaboration.
    - (d) Commissioner.
    - (e) Technical and scientific review groups.
    - (f) Agency plan for statutory compliance.
    - (g) Annual report.
  - 393a. Office of Pediatric Therapeutics.
    - (a) Establishment.
    - (b) Duties.
    - (c) Staff.
  - 394. Scientific review groups.
  - 395. Loan repayment program.
    - (a) In general.
    - (b) Applicability of certain provisions.
    - (c) Authorization of appropriations.
  - 396. Practice of medicine.
  - 397. Contracts for expert review.
    - (a) In general.
    - (b) Review of expert review.

## CHAPTER REFERRED TO IN OTHER SECTIONS

This chapter is referred to in sections 355b, 453, 457, 466, 467, 467f, 601, 607, 620, 679, 802, 811, 823, 829, 830, 902,

1033, 1049, 1052, 1401, 1402, 1403, 1601 of this title; title 7 sections 136a-1, 136v, 138i, 1431c, 5341, 6519, 7653; title 15 sections 70j, 1261, 1263, 1277, 1459, 1460, 2057a, 2057b, 2079; title 18 sections 42, 983; title 19 section 2578a; title 26 sections 170, 4817; title 35 sections 155, 156, 271, 287; title 42 sections 262, 284m, 300aa-22, 300aa-23, 1396r-8, 1786, 3512, 7671.

## SUBCHAPTER I—SHORT TITLE

## § 301. Short title

This chapter may be cited as the Federal Food, Drug, and Cosmetic Act.

(June 25, 1938, ch. 675, § 1, 52 Stat. 1040.)

## EFFECTIVE DATE; POSTPONEMENT IN CERTAIN CASES

Act June 23, 1939, ch. 242, §§ 1, 2, 53 Stat. 853, 854, provided that:

"[SEC. 1] (a) The effective date of the following provisions of the Federal Food, Drug, and Cosmetic Act is hereby postponed until January 1, 1940: Sections 402(c) [342(c) of this title]; 403(e)(1) [343(e)(1) of this title]; 403(g), (h), (i), (j), and (k) [343(g) to (k) of this title]; 501(a), (4) [351(a)(4) of this title]; 502(b), (d), (e), (f), (g), and (h) [352(b), (d) to (h) of this title]; 601(e) [361(e) of this title]; and 602(b) [362(b) of this title].

"(b) The Secretary of Agriculture shall promulgate regulations further postponing to July 1, 1940 the effective date of the provisions of sections 403(e)(1) [343(e)(1) of this title]; 403(g), (h), (i), (j), and (k) [343(g) to (k)]; 502(b), (d), (e), (f), (g), and (h) [352(b), (d) to (h) of this title]; and 602(b) [362(b) of this title] of such Act with respect to lithographed labeling which was manufactured prior to February 1, 1939, and to containers bearing labeling which, prior to February 1, 1939, was lithographed, etched, stamped, pressed, printed, fused or blown on or in such containers, where compliance with such provisions would be unduly burdensome by reason of causing the loss of valuable stocks of such labeling or containers, and where such postponement would not prevent the public interest being adequately served: Provided, That in no case shall such regulations apply to labeling which would not have complied with the requirements of the Food and Drugs Act of June 30, 1906, as amended.

"SEC. 2. (a) The provisions of section 8 [section 10 of this title], paragraph fifth, under the heading 'In the case of food:', of the Food and Drugs Act of June 30, 1906, as amended, and regulations promulgated thereunder, and all other provisions of such Act to the extent that they may relate to the enforcement of such section 8 [section 10 of this title] and of such regulations, shall remain in force until January 1, 1940.

"(b) The provisions of such Act of June 30, 1906, as amended, [sections 1 to 5, 7 to 15, and 372a of this title] to the extent that they impose, or authorize the imposition of, any requirement imposed by section 403(k) of the Federal Food, Drug, and Cosmetic Act [section 343(k) of this title], shall remain in force until January 1, 1940.

"(c) Notwithstanding the provisions of section 1 of this Act, such section shall not apply—

"(1) to the provisions of section 502(d) and (e) of the Federal Food, Drug, and Cosmetic Act [352(d), (e) of this title], insofar as such provisions relate to any substance named in section 8 [section 10 of this title], paragraph second, under the heading 'In the case of drugs:', of the Food and Drugs Act of June 30, 1906, as amended, or a derivative of any such substance; or

"(2) to the provisions of section 502(b), (d), (e), (f), (g), and (h) of the Federal Food, Drug, and Cosmetic Act [352(b), (d) to (h) of this title], insofar as such provisions relate to drugs to which section 505 [355 of this title] of such Act applies."

## EFFECTIVE DATE

Section 902(a) of act June 25, 1938, provided that: "This Act [enacting this chapter and repealing sections